Transgenic Models of Ah Receptor Action

Ah 受体作用的转基因模型

基本信息

项目摘要

DESCRIPTION (provided by applicant): The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that mediates the biological effects of polycyclic aromatic hydrocarbons (PAHs), halogenated-dioxins ("dioxins"), - dibenzofurans, -biphenyls (PCBs), and -diphenylethers. Because of its central role in acute toxicity, teratogenesis and carcinogenesis of a large number of environmental contaminants, mechanistic information about AHR signaling is used by regulatory agencies to establish acceptable exposure levels for these pollutants. The overarching hypothesis of this proposal is that at least three distinct AHR signaling pathways exist that are of toxicological significance to human populations and vertebrate species in general. We propose that these three pathways can be distinguished by their unique impacts on transcriptional profiles within target cell populations and that these pathways can be further defined based upon their dependence on fractional activation of the AHR, by their cellular context, and their influence on gene expression through enhancer elements known as AHREs. The goal of this proposal is to identify biomarkers that reflect exposure to agonists and their induced toxic responses. We will accomplish this through the identification of low and high affinity AHREs in the hepatocyte and endothelial cell compartments of novel recombinant mouse models. To these ends, we propose the following specific aims: Specific Aim 1: Use gene targeting in ES cells to generate recombinant alleles derived from a ligand responsive version of Ahr. Specific Aim 2: Demonstrate the importance of the cellular expression and concentration of AHR. Specific Aim 3: Classify the high and low affinity AHRE batteries using genomic approaches. Specific Aim 4: Provide evidence that environmental AHR agonists can stimulate the endogenous AHR pathway. We propose that the results of this effort will provide new models that will inform the mechanism of dioxin toxicity in humans, characterize DNA signatures of toxicity, and test a novel hypothesis that developmental toxicity arises from interference with the endogenous AHR pathway. Collectively these studies will set the stage for more accurate and informative risk assessment in man.
描述(由申请人提供):芳烃受体(AHR)是一种配体激活的转录因子,介导多环芳烃(PAH)、卤代二恶英(“二恶英”)、-二苯并呋喃、-联苯(PCB)和-二苯醚的生物效应。由于其在大量环境污染物的急性毒性、致畸作用和致癌作用中的核心作用,有关AHR信号传导的机制信息被监管机构用于确定这些污染物的可接受暴露水平。该建议的总体假设是,至少存在三种不同的AHR信号通路,它们对人类种群和脊椎动物物种具有毒理学意义。我们建议,这三种途径可以区分其独特的影响,在靶细胞群内的转录谱,这些途径可以进一步定义的基础上,他们的依赖于分数激活的AHR,他们的细胞环境,和他们的影响,通过增强子元件被称为AHRE的基因表达。该提案的目标是确定反映暴露于激动剂及其诱导的毒性反应的生物标志物。我们将通过在新型重组小鼠模型的肝细胞和内皮细胞隔室中鉴定低亲和力和高亲和力AHRE来实现这一点。为此,我们提出了以下具体目标:具体目标1:在ES细胞中使用基因靶向来产生源自Ahr的配体响应版本的重组等位基因。具体目标2:证明AHR的细胞表达和浓度的重要性。具体目标3:使用基因组方法对高亲和力和低亲和力AHRE电池进行分类。具体目标4:提供环境AHR激动剂可刺激内源性AHR通路的证据。我们建议,这一努力的结果将提供新的模型,将告知二恶英在人类中的毒性机制,表征DNA签名的毒性,并测试一个新的假设,即发育毒性产生的干扰与内源性AHR途径。总的来说,这些研究将为人类更准确和信息丰富的风险评估奠定基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHRISTOPHER A BRADFIELD其他文献

CHRISTOPHER A BRADFIELD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHRISTOPHER A BRADFIELD', 18)}}的其他基金

The PAS Sensor Family and Human Health
PAS 传感器系列与人类健康
  • 批准号:
    10621257
  • 财政年份:
    2017
  • 资助金额:
    $ 33.19万
  • 项目类别:
The PAS Sensor Family and Human Health
PAS 传感器系列与人类健康
  • 批准号:
    10179394
  • 财政年份:
    2017
  • 资助金额:
    $ 33.19万
  • 项目类别:
The PAS Sensor Family and Human Health
PAS 传感器系列与人类健康
  • 批准号:
    10412067
  • 财政年份:
    2017
  • 资助金额:
    $ 33.19万
  • 项目类别:
Transgenic Models of Ah Receptor Action
Ah 受体作用的转基因模型
  • 批准号:
    8974829
  • 财政年份:
    2012
  • 资助金额:
    $ 33.19万
  • 项目类别:
Transgenic Models of Ah Receptor Action
Ah 受体作用的转基因模型
  • 批准号:
    8258122
  • 财政年份:
    2012
  • 资助金额:
    $ 33.19万
  • 项目类别:
Transgenic Models of Ah Receptor Action
Ah 受体作用的转基因模型
  • 批准号:
    8588322
  • 财政年份:
    2012
  • 资助金额:
    $ 33.19万
  • 项目类别:
Summer Research Experience for Minority Undergraduates
少数民族本科生暑期研究经历
  • 批准号:
    8660695
  • 财政年份:
    2011
  • 资助金额:
    $ 33.19万
  • 项目类别:
Identification and Characterization of the Mouse PPCD1 Gene
小鼠 PPCD1 基因的鉴定和表征
  • 批准号:
    8309049
  • 财政年份:
    2011
  • 资助金额:
    $ 33.19万
  • 项目类别:
Identification and Characterization of the Mouse PPCD1 Gene
小鼠 PPCD1 基因的鉴定和表征
  • 批准号:
    8513999
  • 财政年份:
    2011
  • 资助金额:
    $ 33.19万
  • 项目类别:
Identification and Characterization of the Mouse PPCD1 Gene
小鼠 PPCD1 基因的鉴定和表征
  • 批准号:
    8700411
  • 财政年份:
    2011
  • 资助金额:
    $ 33.19万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.19万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.19万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 33.19万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.19万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 33.19万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.19万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.19万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.19万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 33.19万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 33.19万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了